Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ENDRA Life Sciences (NDRA) Non-Current Assets (2016 - 2025)

ENDRA Life Sciences has reported Non-Current Assets over the past 6 years, most recently at $780529.0 for Q4 2021.

  • Quarterly Non-Current Assets rose 40.07% to $780529.0 in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $3.1 million through Dec 2021, up 30.58% year-over-year, with the annual reading at $780529.0 for FY2021, 40.07% up from the prior year.
  • Non-Current Assets was $780529.0 for Q4 2021 at ENDRA Life Sciences, down from $844073.0 in the prior quarter.
  • Over five years, Non-Current Assets peaked at $899592.0 in Q2 2021 and troughed at $211345.0 in Q2 2018.
  • The 5-year median for Non-Current Assets is $420341.5 (2018), against an average of $462796.7.
  • Year-over-year, Non-Current Assets fell 22.32% in 2018 and then soared 146.02% in 2020.
  • A 5-year view of Non-Current Assets shows it stood at $241549.0 in 2017, then rose by 13.12% to $273233.0 in 2018, then skyrocketed by 134.66% to $641170.0 in 2019, then fell by 13.09% to $557240.0 in 2020, then soared by 40.07% to $780529.0 in 2021.
  • Per Business Quant, the three most recent readings for NDRA's Non-Current Assets are $780529.0 (Q4 2021), $844073.0 (Q3 2021), and $899592.0 (Q2 2021).